目次

Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Methodology
Information Sources
Geographic Breakdown

Chapter- 2: Summary and Highlights
Market Overview

Chapter- 3: Market Overview
Introduction
Is There a Problem with Human Blood?
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Challenges in Artificial Blood Development

Chapter- 4: Market Dynamics
Drivers
Barriers
Opportunities
Impact of COVID-19

Chapter- 5: Artificial Blood by Source
Introduction
Artificial Blood Developed from Human Blood
Artificial Blood Developed from Animal Blood
Artificial Blood Developed Using Recombinant Technology

Chapter- 6: Artificial Blood by Type
Introduction
Perfluorocarbon Emulsions
Hemoglobin-based Oxygen Carriers

Chapter- 7: Market Estimation
Introduction
Potential Market for Artificial Blood
Artificial Blood Market, by Source
Artificial Blood Market, by Type
Artificial Blood Market, by Region

Chapter- 8: Emerging Technologies and Developments
Overview
Emerging Technologies

Chapter- 9: Product Analysis
Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Product Analysis of Some of the Products Under Development
Product Description of Some of the Products in Preclinical and Early Phase I Stage

Chapter- 10: Patent Analysis
Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Analysis

Chapter- 11: Competitive Intelligence
Strategic Developments
Competitive Analysis

Chapter- 12: Company Profiles
AURUM BIOSCIENCES
ERYPHARM
HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
HEMARINA
KALOCYTE INC.
NANO SANGUIS S.A
NUVOX PHARMA LLC.
PROLONG PHARMACEUTICALS, LLC
RED C BIOTECH
VIRTECH BIO